Vimirogant (formerly VTP-43742; AGN-242428; VTP43742; AGN242428) is a novel, orally bioactive and potent RORγt inhibitor with immunomodulatory activities and has the potential to be used for the treatment of autoimmune disorders such as MS (multiple sclerosis) and psoriasis. It inhibits RORγt with a Ki of 35 nM an an IC50 of 17 nM, and shows >1000-fold selectivity over RORα and RORβ isoforms.

纯度：≥98%

CAS：1802706-04-2